Cost of cancer care per patient is driven by dose, schedule, and changes in drug cost. Total cost of care by indication is driven by the same factors plus change in number of patients receiving therapy in a given indication.
Over 95% of panitumumab monthly usage is coming from colorectal cancers, with about a 75% share coming from colon cancer and about 20% from rectal cancer. There is less than 2% use in ovarian cancer. Month to month cost per patient has been relatively steady in colorectal cancers, with a slow 5% increase over the three year course. Change in total monthly cost in colorectal cancers is due to steady patient growth over the three years represented here.
Average Sales Price (ASP) is calculated based on wholesale prices 2 quarters ago. ASP+6% is used to establish the ceiling for reimbursement. ASP+6% pricing data are publicly available at www.cms.gov/McrPartBDrugAvgSalesPrice/. ASP is assumed for all graphs.
About the Contributor
IntrinsiQ, part of AmerisourceBergen Specialty Group, is the leading provider of medical oncology clinical information systems and the premier source of oncology data and analysis in the United States.